Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Illumina and Mayo ClinicTo Develop Molecular Diagnostic Tests

By HospiMedica staff writers
Posted on 19 Jan 2007
Illumina, Inc. More...
(San Diego, CA, USA) and Mayo Clinic (Rochester, MI, USA) have signed a diagnostic collaborative agreement to enable the co-development of molecular diagnostic tests for the study of complex diseases.

Illumina will contribute its VeraCode technology and development expertise for the BeadArray and BeadXpress instrument platforms. Mayo Clinic will bring broad knowledge in clinical practice and patient outcome management, along with proficiency in establishing clinical utility of new diagnostic technologies. In addition, Mayo's ability to discover and validate biomarkers offers the potential for both parties to implement important new clinical tests.

Terms of the agreement enable the implementation of new clinical tests within Mayo's clinical practice and Mayo Medical Laboratories. Additionally, Illumina will manufacture and market tests worldwide on Illumina's BeadArray and upcoming BeadXpress Reader.

Illumina's patented BeadArray technology achieves a level of array miniaturization that allows for a new scale of experimentation. An array is a collection of miniaturized test sites arranged on a surface that permits many tests, or assays, to be performed in parallel. By arranging analytic devices into a multi-sample array of arrays format, one can process in parallel thousands to millions of assays, a throughput significantly beyond the capability of any technology known to us.

Illumina's VeraCode technology leverages the power of digital holographic codes to provide a robust detection method for multiplexed assays requiring high precision, accuracy and speed. This technology, combined with Illumina's BeadXpress Reader, supports the rapid detection and analysis of a wide range of assays with industry leading multiplexing capability.

The department of laboratory medicine and pathology at Mayo Clinic maintains an active diagnostic test development program. These activities also incorporate technologies from collaborations with diagnostic and biotechnology companies. Mayo utilizes these proven diagnostic technologies in the care of its patients and offers them to more than 5,000 health care institutions around the world through Mayo Medical Laboratories (MML). Revenue from MML testing is used to support medical education and research at Mayo Clinic.



Related Links:
Illumina
Mayo Clinic

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.